Teva Hit With Suit Over Deal to Curb EpiPen, Nuvigil Competition

Teva Pharmaceutical Industries Ltd. schemed with Mylan NV and Pfizer Inc. to block access to generic versions of EpiPen in exchange for a hold on generics of Teva’s Nuvigil wakefulness medicine, a proposed class action alleged.

The anticompetitive scheme foreclosed generic competition to both EpiPen and Nuvigil for several years longer than legally permitted, forcing purchasers to pay for the branded products when prescriptions could have been filled using cheaper generic options, the complaint filed Wednesday in the US District Court for the Central District of California said.

Teva was already facing another suit filed in 2022 that alleged similar ...